Evolus’ (NASDAQ:EOLS) quiet period is set to end on Tuesday, March 20th. Evolus had issued 5,000,000 shares in its public offering on February 8th. The total size of the offering was $60,000,000 based on an initial share price of $12.00. During the company’s quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

EOLS has been the subject of several recent research reports. Mizuho initiated coverage on shares of Evolus in a report on Monday, March 5th. They set a “buy” rating and a $21.00 target price for the company. JMP Securities began coverage on shares of Evolus in a report on Monday, March 5th. They set an “outperform” rating and a $20.00 target price for the company. Cantor Fitzgerald began coverage on shares of Evolus in a research note on Monday, March 5th. They issued an “overweight” rating and a $25.00 price target on the stock. Finally, SunTrust Banks began coverage on shares of Evolus in a research note on Monday, March 5th. They issued a “buy” rating and a $24.00 price target on the stock.

How to Become a New Pot Stock Millionaire

Shares of Evolus (NASDAQ EOLS) opened at $11.83 on Thursday. Evolus has a one year low of $9.60 and a one year high of $12.97.

ILLEGAL ACTIVITY NOTICE: This piece was first published by Daily Political and is the property of of Daily Political. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.dailypolitical.com/2018/03/14/evolus-incs-eols-quiet-period-set-to-end-on-march-20th.html.

Evolus Company Profile

Evolus, Inc is a medical aesthetics company. The Company is focused on providing physicians and aesthetic procedures and treatments. It also focuses on offering the self-pay aesthetic market and its product candidate, PrabotulinumtoxinA (DWP-450), is an injectable 900 kilodalton, or kDa, botulinum toxin type designed to address the needs of the large and growing facial aesthetics market.

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.